drugset / Trial / NCT03181503

Safety and Efficacy of Nemolizumab in PN

NCT03181503

Phase 2 Completed 70 enrolled Galderma R&D
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The aim of this study is to assess the safety and efficacy of nemolizumab in subjects with prurigo nodularis.

Timeline

Start
2017-10-02
Primary completion
2018-09-26
Completion
2018-09-26

Drugs

EvaluationDrugModalityDoseRoute
Subject Nemolizumab Monoclonal antibody 0.5 mg/kg Subcutaneous

Indications